abiraterone has been researched along with ketoconazole in 26 studies
| Studies (abiraterone) | Trials (abiraterone) | Recent Studies (post-2010) (abiraterone) | Studies (ketoconazole) | Trials (ketoconazole) | Recent Studies (post-2010) (ketoconazole) |
|---|---|---|---|---|---|
| 942 | 97 | 854 | 6,202 | 706 | 1,269 |
| 942 | 97 | 854 | 149 | 0 | 120 |
| Protein | Taxonomy | abiraterone (IC50) | ketoconazole (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 1 | Homo sapiens (human) | 2.6 | |
| 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial | Homo sapiens (human) | 0.34 | |
| 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial | Mus musculus (house mouse) | 0.36 | |
| Bile salt export pump | Homo sapiens (human) | 3.44 | |
| Steroid 17-alpha-hydroxylase/17,20 lyase | Homo sapiens (human) | 1.5811 | |
| ATP-dependent translocase ABCB1 | Mus musculus (house mouse) | 6.7 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 4.6771 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.2303 | |
| Steroid 21-hydroxylase | Homo sapiens (human) | 6.655 | |
| Cytochrome P450 2C8 | Homo sapiens (human) | 0.06 | |
| Aromatase | Homo sapiens (human) | 1.4111 | |
| Steroid 17-alpha-hydroxylase/17,20 lyase | Rattus norvegicus (Norway rat) | 2.0802 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 5.425 | |
| Cholesterol side-chain cleavage enzyme, mitochondrial | Rattus norvegicus (Norway rat) | 3.32 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 1.067 | |
| Cytochrome P450 2A2 | Rattus norvegicus (Norway rat) | 0.456 | |
| Cytochrome P450 11B1, mitochondrial | Bos taurus (cattle) | 0.38 | |
| Cytochrome P450 11B1, mitochondrial | Homo sapiens (human) | 0.4519 | |
| Translocator protein | Rattus norvegicus (Norway rat) | 3.76 | |
| Cytochrome P450 7A1 | Rattus norvegicus (Norway rat) | 1.2975 | |
| Cytochrome P450 11B2, mitochondrial | Homo sapiens (human) | 0.5179 | |
| ATP-dependent translocase ABCB1 | Mus musculus (house mouse) | 3.8 | |
| Thromboxane-A synthase | Homo sapiens (human) | 2.165 | |
| Gonadotropin-releasing hormone receptor | Rattus norvegicus (Norway rat) | 2 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.531 | |
| Type-1 angiotensin II receptor | Oryctolagus cuniculus (rabbit) | 0.0078 | |
| Cytochrome P450 4F2 | Homo sapiens (human) | 1.6 | |
| 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial | Homo sapiens (human) | 0.4144 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1.9036 | |
| Lanosterol 14-alpha demethylase | Homo sapiens (human) | 0.19 | |
| Cytochrome P450 7A1 | Mus musculus (house mouse) | 1.2975 | |
| Lanosterol 14-alpha demethylase | Rattus norvegicus (Norway rat) | 0.083 | |
| Epoxide hydrolase 1 | Homo sapiens (human) | 0.04 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 2.774 | |
| Cytochrome P450 3A5 | Homo sapiens (human) | 0.2535 | |
| Bifunctional epoxide hydrolase 2 | Homo sapiens (human) | 0.04 | |
| Sterol 14-alpha demethylase | Trypanosoma cruzi strain CL Brener | 0.014 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (7.69) | 18.2507 |
| 2000's | 9 (34.62) | 29.6817 |
| 2010's | 14 (53.85) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Barrie, SE; Jarman, M; Potter, GA; Rowlands, MG | 1 |
| Brodie, AM; Chopra, P; Farquhar, R; Gediya, LK; Guo, Z; Handratta, VD; Kataria, R; Newman, D; Njar, VC; Qiu, Y; Vasaitis, TS | 1 |
| Hansen, K; Hartmann, RW; Hille, UE; Jagusch, C; Müller-Vieira, U; Negri, M; Pinto-Bazurco Mendieta, MA; Schmidt, D | 1 |
| Bartels, M; Cavalli, A; Hartmann, RW; Hille, UE; Hu, Q; Jagusch, C; Jahn-Hoffmann, K; Lauterbach, T; Müller-Vieira, U; Negri, M; Pinto-Bazurco Mendieta, MA; Recanatini, M; Rodenwaldt, B; Schmidt, D | 1 |
| Hartmann, RW; Jagusch, C; Lauterbach, T; Müller-Vieira, U; Negri, M; Pinto-Bazurco Mendieta, MA | 1 |
| Bartels, M; Hartmann, RW; Hu, Q; Jahn-Hoffmann, K; Lauterbach, T; Müller-Vieira, U; Negri, M; Olgen, S; Zhuang, Y | 1 |
| Bartels, M; Hartmann, RW; Hille, UE; Hu, Q; Lauterbach, T; Müller-Vieira, U; Negri, M; Vock, C | 1 |
| Hartmann, RW; Hille, UE; Hu, Q; Jagusch, C; Yin, L | 1 |
| Hartmann, RW; Haupenthal, J; Hille, UE; Hu, Q; Jagusch, C | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Frank, E; Kovács, D; Kovács, I; Szabó, N; Szécsi, M; Wölfling, J; Zupkó, I | 1 |
| Brodie, AM; Njar, VC | 1 |
| Frank, É; Kovács, D; Schelz, Z; Szabó, N; Szécsi, M; Wölfling, J; Zupkó, I | 1 |
| Barrie, SE; Dowsett, M; Goddard, PM; Haynes, BP; Jarman, M; Potter, GA | 1 |
| Hosaka, M; Takeda, M | 1 |
| Ehmer, PB; Haidar, S; Hartmann, RW | 1 |
| Ryan, CJ; Van Allen, EM | 1 |
| Fong, L; Kantoff, P; Kheoh, T; Kim, J; Lee, G; Martins, V; Molina, A; Raynaud, F; Rosenberg, JE; Ryan, CJ; Small, EJ; Smith, MR | 1 |
| Miller, K | 1 |
| Kim, W; Ryan, CJ | 1 |
| Alimohamed, N; Atenafu, EG; Joshua, AM; Knox, JJ; Leibowitz-Amit, R; Seah, JA; Sridhar, SS; Tannock, IF; Templeton, AJ; Vera-Badillo, FE | 1 |
| Balk, SP; Bubley, GJ; Cai, C; Chen, EJ; Gao, S; Kantoff, PW; Lis, RL; Loda, M; Montgomery, RB; Nelson, PS; Schaefer, R; Sowalsky, AG; Taplin, ME; Troncoso, P; True, LD; Voznesensky, O; Ye, H | 1 |
| Antonarakis, ES; Denmeade, SR; Luber, B; Teply, BA | 1 |
| Abbott, DH; Bird, IM | 1 |
| Chapman, JG; Guengerich, FP; McCarty, KD; Tateishi, Y | 1 |
5 review(s) available for abiraterone and ketoconazole
| Article | Year |
|---|---|
[Inhibitors of the key enzymes of androgen synthesis: potential agents as targets for prostate cancer].
Topics: 17-Hydroxysteroid Dehydrogenases; Androgen Antagonists; Androstenes; Androstenols; Animals; Antineoplastic Agents, Hormonal; Carbazoles; Enzyme Inhibitors; Humans; Imidazoles; Ketoconazole; Male; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Testosterone | 2000 |
Novel secondary hormonal therapy in advanced prostate cancer: an update.
Topics: Androgen Antagonists; Androstenes; Androstenols; Disease Progression; Humans; Ketoconazole; Male; Prostatic Neoplasms; Receptors, Androgen | 2009 |
[Castration resistant prostate cancer 2011].
Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Cancer Vaccines; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Humans; Ketoconazole; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Taxoids; Tissue Extracts | 2011 |
Androgen receptor directed therapies in castration-resistant metastatic prostate cancer.
Topics: Androgen Receptor Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Docetaxel; Drug Resistance, Neoplasm; Humans; Ketoconazole; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Taxoids; Thiohydantoins | 2012 |
The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.
Topics: Adrenal Hyperplasia, Congenital; Androstadienes; Androstenes; Antineoplastic Agents; Benzimidazoles; Cytochrome P-450 CYP3A Inhibitors; Drug Therapy, Combination; Humans; Hydrocortisone; Imidazoles; Ketoconazole; Male; Naphthalenes; Prednisone; Prostate; Prostatic Neoplasms; Protective Factors; Steroid 17-alpha-Hydroxylase; Triazoles | 2016 |
1 trial(s) available for abiraterone and ketoconazole
| Article | Year |
|---|---|
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Agents; Dose-Response Relationship, Drug; Humans; Ketoconazole; Male; Middle Aged; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Treatment Outcome | 2010 |
20 other study(ies) available for abiraterone and ketoconazole
| Article | Year |
|---|---|
Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer.
Topics: Cytochrome P-450 Enzyme Inhibitors; Humans; Magnetic Resonance Spectroscopy; Male; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Steroids; Structure-Activity Relationship; Testis | 1995 |
Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Androstadienes; Animals; Antineoplastic Agents; Azoles; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Humans; Isoenzymes; Male; Mice; Mice, SCID; Mutation; Prostatic Neoplasms; Pyrazines; Radioligand Assay; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Structure-Activity Relationship; Tissue Distribution; Transcription, Genetic; Transcriptional Activation; Xenograft Model Antitumor Assays | 2005 |
Synthesis, biological evaluation and molecular modelling studies of novel ACD- and ABD-ring steroidomimetics as inhibitors of CYP17.
Topics: Biomimetic Materials; Enzyme Inhibitors; Heterocyclic Compounds; Humans; Liver; Models, Molecular; Naphthalenes; Progesterone; Steroid 17-alpha-Hydroxylase | 2008 |
Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure.
Topics: Binding Sites; Biological Availability; Enzyme Inhibitors; Heterocyclic Compounds; Humans; Imidazoles; Inhibitory Concentration 50; Liver; Models, Molecular; Polycyclic Aromatic Hydrocarbons; Steroid 17-alpha-Hydroxylase; Testosterone | 2008 |
Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.
Topics: Androstenes; Androstenols; Biphenyl Compounds; Enzyme Inhibitors; Humans; Male; Models, Molecular; Prostatic Neoplasms; Recombinant Proteins; Steroid 17-alpha-Hydroxylase | 2008 |
Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17)--part II: Core rigidification and influence of substituents at the methylene bridge.
Topics: Animals; Binding Sites; Biphenyl Compounds; Enzyme Inhibitors; Humans; Imidazoles; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Male; Models, Molecular; Protein Structure, Secondary; Rats; Spectrometry, Mass, Electrospray Ionization; Spectrophotometry, Infrared; Steroid 17-alpha-Hydroxylase; Testosterone | 2008 |
Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls.
Topics: Biphenyl Compounds; Catalytic Domain; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Design; Enzyme Inhibitors; Humans; Models, Molecular; Steroid 11-beta-Hydroxylase; Steroid 17-alpha-Hydroxylase; Structure-Activity Relationship; Substrate Specificity | 2009 |
Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.
Topics: Antineoplastic Agents, Hormonal; Biphenyl Compounds; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Pyridines; Spectrometry, Mass, Electrospray Ionization; Steroid 17-alpha-Hydroxylase; Structure-Activity Relationship; Substrate Specificity | 2010 |
Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.
Topics: Androgen Antagonists; Animals; Biphenyl Compounds; Cell Line; Cricetinae; Cricetulus; Humans; Imidazoles; In Vitro Techniques; Male; Microsomes; Prostatic Neoplasms; Pyridines; Steroid 11-beta-Hydroxylase; Steroid 17-alpha-Hydroxylase; Structure-Activity Relationship; Testis | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
An efficient approach to novel 17-5'-(1',2',4')-oxadiazolyl androstenes via the cyclodehydration of cytotoxic O-steroidacylamidoximes, and an evaluation of their inhibitory action on 17α-hydroxylase/C₁₇,₂₀-lyase.
Topics: Androstenes; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cyclization; Dehydration; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Inhibitors; HeLa Cells; Humans; Male; MCF-7 Cells; Molecular Conformation; Oximes; Rats; Rats, Wistar; Steroid 17-alpha-Hydroxylase; Structure-Activity Relationship; Testis | 2013 |
Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
Topics: Androgen Receptor Antagonists; Androstadienes; Benzimidazoles; Clinical Trials as Topic; Drug Discovery; Humans; Male; Molecular Structure; Molecular Targeted Therapy; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Steroid 17-alpha-Hydroxylase; Tissue Distribution | 2015 |
Synthesis of novel 17-(4'-formyl)pyrazolylandrosta-5,16-dienes and their derivatives as potent 17α-hydroxylase/C17,20-lyase inhibitors or antiproliferative agents depending on the substitution pattern of the heteroring.
Topics: Androstadienes; Animals; Antineoplastic Agents; Cell Proliferation; Enzyme Inhibitors; Female; Humans; Hydrazines; Lyases; Male; Pyrazoles; Rats; Steroid 17-alpha-Hydroxylase; Steroids; Structure-Activity Relationship | 2016 |
Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase).
Topics: Abiraterone Acetate; Adrenal Glands; Aldehyde-Lyases; Androgens; Androstadienes; Androstenes; Androstenols; Animals; Cytochrome P-450 Enzyme Inhibitors; Flutamide; Guinea Pigs; Ketoconazole; Kidney; Luteinizing Hormone; Male; Mice; Orchiectomy; Organ Size; Prostate; Seminal Vesicles; Steroid 17-alpha-Hydroxylase; Testis; Testosterone | 1994 |
Novel steroidal pyrimidyl inhibitors of P450 17 (17 alpha-hydroxylase/C17-20-lyase).
Topics: Androstenes; Androstenols; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Ketoconazole; Male; Steroid 17-alpha-Hydroxylase; Structure-Activity Relationship | 2001 |
Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole.
Topics: Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Ketoconazole; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2014 |
Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; DNA Helicases; DNA-Binding Proteins; Drug Resistance, Neoplasm; Dutasteride; Humans; Ketoconazole; Leuprolide; Male; Middle Aged; Mutation; Progesterone; Prostatic Neoplasms, Castration-Resistant; PTEN Phosphohydrolase; Receptors, Androgen; Steroid 17-alpha-Hydroxylase | 2015 |
Singapore Cancer Network (SCAN) Guidelines for the Management of Advanced Castrate-Resistant Prostate Cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Cancer Vaccines; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Ketoconazole; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Singapore; Taxoids; Tissue Extracts | 2015 |
The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Ketoconazole; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Stepwise binding of inhibitors to human cytochrome P450 17A1 and rapid kinetics of inhibition of androgen biosynthesis.
Topics: Androgens; Androstenes; Antineoplastic Agents, Hormonal; Catalytic Domain; Cytochrome P-450 CYP3A; Enzyme Inhibitors; Humans; Imidazoles; Ketoconazole; Kinetics; Male; Naphthalenes; Pregnenolone; Progesterone; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase | 2021 |